Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Methylphenidate (MPH) has been found to be an effective medication for attention-deficit/hyperactivity disorder (ADHD). However, there are neither consistent nor sufficient findings on whether psychiatric comorbidities and associated cognitive functions of ADHD are related to treatment response to MPH in ADHD children.
Objectives: This study investigated whether psychiatric comorbidities, IQ, and neurocognitive deficits are related to treatment response to MPH in ADHD children. In some ways, it is preferable to have a drug that the effectiveness of which to a disorder is not affected by its associated cognitive functions and psychiatric comorbidities. On the other hand, it is likely that the baseline symptom severity of ADHD is associated with the effectiveness of MPH treatment on the symptoms post treatment.
Methods: A total of 149 Chinese boys (aged 6-12 years) with ADHD, combined type, and normal IQ participated in this study. Assessment of ADHD symptom severity was conducted pre and post MPH treatment, while assessment of psychiatric comorbidities, IQ, and neurocognitive deficits was performed in a non-medicated condition. Treatment response was defined as the ADHD symptom severity post MPH treatment.
Results: Results indicated that MPH treatment was effective, significantly improving the ADHD condition. Yet, comorbid disorders, IQ, and neurocognitive deficits were not related to MPH treatment response on ADHD symptoms. These findings indicated that the effectiveness of MPH was not affected by psychiatric comorbidities and associated cognitive functions of ADHD. Instead, as expected, it was the baseline symptom severity that was mainly related to the treatment response, ie, the milder the baseline condition, the better the treatment response.
Conclusion: The current findings positively endorse the widespread clinical use of MPH for treating ADHD. It improves the behavioral symptoms of ADHD regardless of varying psychiatric comorbidities, IQ, and neurocognitive deficits.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396959 | PMC |
| http://dx.doi.org/10.2147/NDT.S128086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol for a randomized controlled trial of patient-portal-based screening for substance use among people with HIV.
Front Public Health
September 2025
Department of Medicine, University of Chicago, Chicago, IL, United States.
Background: Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV-S) is a research project funded by the National Institute for Drug Abuse to implement and evaluate multi-level interventions to decrease barriers to substance use screening and treatment for PLWH. At its center is a multidomain intervention addressing digital, sociocultural, and health care system environments, at individual, interpersonal, and community levels. ePORTAL HIV-S has four overall goals; this manuscript describes the protocol specifically for the randomized control trial (RCT) portion of the study.
View Article and Find Full Text PDFPrenatal environmental risk for adolescent attention, thought, and substance use problems: A mixtures approach to coexposure and psychiatric comorbidities.
Environ Epidemiol
October 2025
Department of Psychiatry and Behavioral Health, The Ohio State University, Ohio.
Background: Prospective studies suggest that prenatal exposure to chemical neurotoxicants and maternal stress increase risk for psychiatric problems. However, most studies have focused on childhood outcomes, leaving adolescence-a critical period for the emergence or worsening of psychiatric symptoms-relatively understudied. The complexity of prenatal coexposures and adolescent psychiatric comorbidities, particularly among structurally marginalized populations with high exposure burdens, remains poorly understood.
View Article and Find Full Text PDFAssessing Severity in Anorexia Nervosa Using Alternative Criteria to the DSM-5 in a Cross-Sectional Study.
Int J Eat Disord
September 2025
Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital, Montpellier, France.
Objective: This study compared overvaluation of weight and shape (OWS), drive for thinness (DT), and their combination (OWS-DT) as alternative severity classifications for anorexia nervosa (AN) to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) severity classification.
Method: 312 AN treatment-seeking outpatients (mean age = 26.8, SD = 10.
Rethinking Burning Mouth Syndrome: A Nociplastic Pain Disorder Shaped by Sexual Dimorphism.
Oral Dis
September 2025
Sunlight Brain Research Center, Hofu, Yamaguchi, Japan.
Identifying levels of alcohol use disorder severity in electronic health records.
Subst Abuse Treat Prev Policy
September 2025
Centre for Interdisciplinary Addiction Research (ZIS), Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, 20246, Hamburg, Germany.
Background: Alcohol use disorder (AUD) is conceptualized as a dimensional phenomenon in the DSM-5, but electronic health records (EHRs) rely on binary AUD definitions according to the ICD-10. The present study classifies AUD severity levels using EHR data and tests whether increasing AUD severity levels are linked with increased comorbidity.
Methods: Billing data from two German statutory health insurance companies in Hamburg included n = 21,954 adults diagnosed with alcohol-specific conditions between 2017 and 2021.